TLG Capital has finalised its latest round of financing in Ugandan pharmaceuticals manufacturer Quality Chemicals Industries (QCIL), raising its stake in the company to 12.5%.
The investor has injected the new funding following QCIL’s achievement of milestones set up by the TLG when it first backed the company. The latest tranche is expected to boost QCIL’s production, with the company looking to triple its production from the current two million tablets a day to 18 million in 2013.
QCIL is looking to invest almost $80 million in its expansion program over the next two years. About $30 million will be injected in capacity expansion, while $50 million will fund a new pharmaceutical ingredients production line. The growth will primarily be funded organically.
TLG initially invested in the QCIL in 2009 and held an option to invest more tranches based on the performance. The company is also part-owned by South African private equity house Capitalworks Investment Partners and Indian pharmaceutical company Cipla. QCIL last year received endorsement from the World Health Organization for the manufacture of its antiretroviral and anti-malarial drugs.
“We are impressed by the management team’s ability to execute on the growth and expansion strategy much earlier than expected and are confident that QCIL will continue to build upon this success, including their plans for increased production capacity,” said Afsane Jetha TLG’s chief operations officer.
Founded in 1998, QCIL established its first plant in 2007 and manufactures triple-combination HIV antiretroviral drugs and anti-malarial drugs under license from Cipla India. The company is headquartered in Kampala and employs about 300 people.